Jon Allard1, Charlotte Lawthom2,3, William Henley4, Brendan Mclean5, Sharon Hudson1, Phil Tittensor6, Sanjeev Rajakulendran7, Shan Ellawela8, Adrian Pace9, Rohit Shankar1,4. 1. Cornwall Intellectual Disability & Epilepsy Research (CIDER) Centre Cornwall Partnership NHS Foundation Trust, Bodmin, UK. 2. Swansea University, Swansea, UK. 3. Aneurin Bevan University Health Board, Newport, UK. 4. University of Exeter Medical School, Truro, UK. 5. Royal Cornwall Hospital NHS Foundation Trust, Truro, UK. 6. The Royal Wolverhampton NHS Trust, Truro, UK. 7. The National Hospital for Neurology and Neurosurgery, University College Hospitals NHS Foundation Trust, London, UK. 8. The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne, UK. 9. Salford Royal NHS Foundation Trust, Salford, UK.
Abstract
BACKGROUND: A quarter of people with intellectual disability (ID) have epilepsy, compared to approximately one in a hundred across the general population. Evidence for the safe and effective prescribing of antiepileptic drugs (AEDs) for those with ID is, however, limited. AIMS OF STUDY: This study seeks to strengthen the research evidence around Eslicarbazepine Acetate (ESL), a new AED, by comparing response of individuals with ID to those from the general population who do not have ID. METHODS: A single data set was created through retrospective data collection from English and Welsh NHS Trusts. The UK-based Epilepsy Database Research Register (Ep-ID) data collection and analysis method were used. RESULTS: Data were collected for 93 people (36 ID and 57 'no ID'). Seizure improvement of '>50%' was higher at 12 months for 'no ID' participants (56%), compared to ID participants (35%). Retention rates were slightly higher for those with ID (56% compared to 53%). Neither difference was significant. CONCLUSIONS: Tolerance and Efficacy for ID and 'no ID' people in our data set were similar. Seizure improvement and retention rates were slightly lower than that found in other European data sets, but findings strengthen the evidence for the use of ESL in the ID population.
BACKGROUND: A quarter of people with intellectual disability (ID) have epilepsy, compared to approximately one in a hundred across the general population. Evidence for the safe and effective prescribing of antiepileptic drugs (AEDs) for those with ID is, however, limited. AIMS OF STUDY: This study seeks to strengthen the research evidence around Eslicarbazepine Acetate (ESL), a new AED, by comparing response of individuals with ID to those from the general population who do not have ID. METHODS: A single data set was created through retrospective data collection from English and Welsh NHS Trusts. The UK-based Epilepsy Database Research Register (Ep-ID) data collection and analysis method were used. RESULTS: Data were collected for 93 people (36 ID and 57 'no ID'). Seizure improvement of '>50%' was higher at 12 months for 'no ID' participants (56%), compared to ID participants (35%). Retention rates were slightly higher for those with ID (56% compared to 53%). Neither difference was significant. CONCLUSIONS: Tolerance and Efficacy for ID and 'no ID' people in our data set were similar. Seizure improvement and retention rates were slightly lower than that found in other European data sets, but findings strengthen the evidence for the use of ESL in the ID population.